Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis

Anderson P Jones, Stephanie Trend, Scott N Byrne, Marzena J Fabis-Pedrini, Sian Geldenhuys, David Nolan, David R Booth, William M Carroll, Robyn M Lucas, Allan G Kermode, Prue H Hart

Research output: Contribution to journalArticle

Abstract

Development of multiple sclerosis (MS) is frequently preceded by an acute or subacute neurological disturbance referred to as clinically isolated syndrome (CIS). The specific immunological disturbances present in CIS remain underexamined. This study analysed peripheral blood mononuclear cells fromn=18 treatment-naive individuals with recently diagnosed CIS (

Original languageEnglish
Article numbere143
JournalClinical & Translational Immunology
Volume6
Issue number5
DOIs
Publication statusPublished - May 2017

Fingerprint

Regulatory T-Lymphocytes
Multiple Sclerosis
Blood Cells
Therapeutics

Cite this

Jones, Anderson P ; Trend, Stephanie ; Byrne, Scott N ; Fabis-Pedrini, Marzena J ; Geldenhuys, Sian ; Nolan, David ; Booth, David R ; Carroll, William M ; Lucas, Robyn M ; Kermode, Allan G ; Hart, Prue H. / Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome : clues to the development of multiple sclerosis. In: Clinical & Translational Immunology. 2017 ; Vol. 6, No. 5.
@article{725ef4ca14934e0faaf8dd2091f0851f,
title = "Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis",
abstract = "Development of multiple sclerosis (MS) is frequently preceded by an acute or subacute neurological disturbance referred to as clinically isolated syndrome (CIS). The specific immunological disturbances present in CIS remain underexamined. This study analysed peripheral blood mononuclear cells fromn=18 treatment-naive individuals with recently diagnosed CIS (",
author = "Jones, {Anderson P} and Stephanie Trend and Byrne, {Scott N} and Fabis-Pedrini, {Marzena J} and Sian Geldenhuys and David Nolan and Booth, {David R} and Carroll, {William M} and Lucas, {Robyn M} and Kermode, {Allan G} and Hart, {Prue H}",
year = "2017",
month = "5",
doi = "10.1038/cti.2017.18",
language = "English",
volume = "6",
journal = "Clinical & Translational Immunology",
issn = "2050-0068",
publisher = "John Wiley & Sons",
number = "5",

}

Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome : clues to the development of multiple sclerosis. / Jones, Anderson P; Trend, Stephanie; Byrne, Scott N; Fabis-Pedrini, Marzena J; Geldenhuys, Sian; Nolan, David; Booth, David R; Carroll, William M; Lucas, Robyn M; Kermode, Allan G; Hart, Prue H.

In: Clinical & Translational Immunology, Vol. 6, No. 5, e143, 05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome

T2 - clues to the development of multiple sclerosis

AU - Jones, Anderson P

AU - Trend, Stephanie

AU - Byrne, Scott N

AU - Fabis-Pedrini, Marzena J

AU - Geldenhuys, Sian

AU - Nolan, David

AU - Booth, David R

AU - Carroll, William M

AU - Lucas, Robyn M

AU - Kermode, Allan G

AU - Hart, Prue H

PY - 2017/5

Y1 - 2017/5

N2 - Development of multiple sclerosis (MS) is frequently preceded by an acute or subacute neurological disturbance referred to as clinically isolated syndrome (CIS). The specific immunological disturbances present in CIS remain underexamined. This study analysed peripheral blood mononuclear cells fromn=18 treatment-naive individuals with recently diagnosed CIS (

AB - Development of multiple sclerosis (MS) is frequently preceded by an acute or subacute neurological disturbance referred to as clinically isolated syndrome (CIS). The specific immunological disturbances present in CIS remain underexamined. This study analysed peripheral blood mononuclear cells fromn=18 treatment-naive individuals with recently diagnosed CIS (

U2 - 10.1038/cti.2017.18

DO - 10.1038/cti.2017.18

M3 - Article

VL - 6

JO - Clinical & Translational Immunology

JF - Clinical & Translational Immunology

SN - 2050-0068

IS - 5

M1 - e143

ER -